Skip to main content
Erschienen in: International Ophthalmology 1/2024

01.12.2024 | Original Paper

Effect of mindfulness-based stress reduction on acute central serous chorioretinopathy: a randomized control trial

verfasst von: Delil Özcan, Murat Karapapak

Erschienen in: International Ophthalmology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the positive effects of mindfulness-based stress reduction (MBSR) on the structural and functional outcomes of patients with central serous chorioretinopathy (CSCR).

Methods

This study included 60 patients with CSCR who were randomly allocated to one of two groups: MBSR or control (which did not practice MBSR). These groups were then evaluated in terms of best corrected visual acuity (BCVA) and central macular thickness (CMT) at months 1, 3, and 6.

Results

There were no significant differences in BCVA or mean CMT between the groups at the beginning of the study (p = 0.615 and p = 0.561, respectively). There were statistically significant differences between the groups in terms of BCVA at 1, 3, and 6 months (p = 0.018, p = 0.001, and p = 0.002, respectively). There were also significant differences in the mean CMT across the groups at the first, third, and sixth months (p < 0.001, p = 0.001, and p < 0.001, respectively).

Conclusion

MBSR may have beneficial outcomes in the early treatment of patients with CSCR, resulting in faster resolution of subretinal fluid and enhancement of BCVA.
Literatur
1.
Zurück zum Zitat Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118CrossRefPubMed Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118CrossRefPubMed
2.
Zurück zum Zitat Daruich A, Matet A, Marchionno L, De Azevedo J-D, Ambresin A, Mantel I et al (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37:1905–1915CrossRefPubMedPubMedCentral Daruich A, Matet A, Marchionno L, De Azevedo J-D, Ambresin A, Mantel I et al (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37:1905–1915CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770CrossRefPubMed van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770CrossRefPubMed
4.
Zurück zum Zitat Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 28:944–957CrossRefPubMed Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 28:944–957CrossRefPubMed
5.
Zurück zum Zitat Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dabir S et al (2015) Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: Safety profile and treatment outcome. Eye 29:258–265CrossRefPubMedPubMedCentral Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dabir S et al (2015) Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: Safety profile and treatment outcome. Eye 29:258–265CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC (2015) A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol 99:848–852CrossRefPubMed Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC (2015) A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol 99:848–852CrossRefPubMed
7.
Zurück zum Zitat Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L et al (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double blind, placebo-controlled trial. Lancet 395:294–303CrossRefPubMed Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L et al (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double blind, placebo-controlled trial. Lancet 395:294–303CrossRefPubMed
8.
Zurück zum Zitat Chhablani J, Rani PK, Mathai A, Jalali S, Kozak I (2014) Navigated focal laser photocoagulation for central serous chorioretinopathy. Clin Ophthalmol 8:1543–1547CrossRefPubMedPubMedCentral Chhablani J, Rani PK, Mathai A, Jalali S, Kozak I (2014) Navigated focal laser photocoagulation for central serous chorioretinopathy. Clin Ophthalmol 8:1543–1547CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Conrad R, Geiser F, Kleiman A, Zur B, Karpawitz-Godt A (2014) Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. Sci World J 2014:631687CrossRef Conrad R, Geiser F, Kleiman A, Zur B, Karpawitz-Godt A (2014) Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. Sci World J 2014:631687CrossRef
11.
Zurück zum Zitat Nongrem G, Surve A, Venkatesh P, Sagar R, Yadav RK, Chawla R, Vohra R, Kumar A (2021Dec) Effect of short-term meditation training in central serous chorioretinopathy. Indian J Ophthalmol 69(12):3559–3563CrossRefPubMedPubMedCentral Nongrem G, Surve A, Venkatesh P, Sagar R, Yadav RK, Chawla R, Vohra R, Kumar A (2021Dec) Effect of short-term meditation training in central serous chorioretinopathy. Indian J Ophthalmol 69(12):3559–3563CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Yoshioka H, Katsume Y, Akune H (1982) Experimental central serous chorioretinopathy in monkey eyes: Fluorescein angiographic findings. Ophthalmologica 185:168–178CrossRefPubMed Yoshioka H, Katsume Y, Akune H (1982) Experimental central serous chorioretinopathy in monkey eyes: Fluorescein angiographic findings. Ophthalmologica 185:168–178CrossRefPubMed
13.
Zurück zum Zitat Kutz I, Borysenko JZ, Benson H (1985) Meditation and psychotherapy: a rationale for the integration of dynamic psychotherapy, the relaxation response, and mindfulness meditation. Am J Psychiatr. 142(1):1e8 Kutz I, Borysenko JZ, Benson H (1985) Meditation and psychotherapy: a rationale for the integration of dynamic psychotherapy, the relaxation response, and mindfulness meditation. Am J Psychiatr. 142(1):1e8
14.
Zurück zum Zitat Gagrani M, Faiq MA, Sidhu T, Dada R, Yadav RK, Sihota R et al (2018) Meditation enhances brain oxygenation, upregulates BDNF and improves quality of life in patients with primary open angle glaucoma: A randomized controlled trial. Restor Neurol Neurosci 36:741–753PubMed Gagrani M, Faiq MA, Sidhu T, Dada R, Yadav RK, Sihota R et al (2018) Meditation enhances brain oxygenation, upregulates BDNF and improves quality of life in patients with primary open angle glaucoma: A randomized controlled trial. Restor Neurol Neurosci 36:741–753PubMed
15.
Zurück zum Zitat Dada T, Mittal D, Mohanty K, Faiq MA, Bhat MA, Yadav RK et al (2018) Mindfulness meditation reduces intraocular pressure, lowers stress biomarkers and modulates gene expression in glaucoma: a randomized controlled trial. J Glaucoma 27:1061–1067CrossRefPubMed Dada T, Mittal D, Mohanty K, Faiq MA, Bhat MA, Yadav RK et al (2018) Mindfulness meditation reduces intraocular pressure, lowers stress biomarkers and modulates gene expression in glaucoma: a randomized controlled trial. J Glaucoma 27:1061–1067CrossRefPubMed
16.
Zurück zum Zitat Dudani AI, Hussain N, Ramakrishnan M, Telang O, Patil VM, Dudani K, Jadhav B, Gholap V (2021) Psychiatric evaluation in patients with central serous chorioretinopathy in Asian Indians. Indian J Ophthalmol 69(5):1204–1207CrossRefPubMedPubMedCentral Dudani AI, Hussain N, Ramakrishnan M, Telang O, Patil VM, Dudani K, Jadhav B, Gholap V (2021) Psychiatric evaluation in patients with central serous chorioretinopathy in Asian Indians. Indian J Ophthalmol 69(5):1204–1207CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Tekin K, Sekeroglu MA, Cankaya AB, Teke MY, Doguizi S, Yilmazbas P (2018) Intravitreal bevacizumab and ranibizumab in the treatment of acute central serous chorioretihopathy: a single center retrospective study. Semin Ophthalmol 33(2):265–270PubMed Tekin K, Sekeroglu MA, Cankaya AB, Teke MY, Doguizi S, Yilmazbas P (2018) Intravitreal bevacizumab and ranibizumab in the treatment of acute central serous chorioretihopathy: a single center retrospective study. Semin Ophthalmol 33(2):265–270PubMed
18.
Zurück zum Zitat Azam MA, Katz J, Fashler SR, Changoor T, Azargive S, Ritvo P (2015) Heart rate variability is enhanced in controls but not maladaptive perfectionists during briefmindfulness meditation following stress-induction: a stratified-randomized trial. Int J Psychophysiol Off J Int Organ Psychophysiol 98(1):27–34 Azam MA, Katz J, Fashler SR, Changoor T, Azargive S, Ritvo P (2015) Heart rate variability is enhanced in controls but not maladaptive perfectionists during briefmindfulness meditation following stress-induction: a stratified-randomized trial. Int J Psychophysiol Off J Int Organ Psychophysiol 98(1):27–34
19.
Zurück zum Zitat Dada T, Ramesh P, Shakrawal J (2020) Meditation: a polypill for comprehensive management of glaucoma patients. J Glaucoma 29(2):133–140CrossRefPubMed Dada T, Ramesh P, Shakrawal J (2020) Meditation: a polypill for comprehensive management of glaucoma patients. J Glaucoma 29(2):133–140CrossRefPubMed
Metadaten
Titel
Effect of mindfulness-based stress reduction on acute central serous chorioretinopathy: a randomized control trial
verfasst von
Delil Özcan
Murat Karapapak
Publikationsdatum
01.12.2024
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 1/2024
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-024-03102-z

Weitere Artikel der Ausgabe 1/2024

International Ophthalmology 1/2024 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.